Status:
COMPLETED
BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer
Lead Sponsor:
Heidelberg University
Conditions:
Thyroid Cancer
Eligibility:
All Genders
24-69 years
Brief Summary
Papillary thyroid cancer (PTC) is the most common neoplasia in the thyroid gland. The combination of surgery, followed by radioiodine therapy (RIT) and thyroid-stimulating hormone (TSH) suppressive th...
Eligibility Criteria
Inclusion
- Eligible criteria for radioiodine-refractory patients included:
- PTC
- no response to former RIT
- decrease or loss of initial sufficient RI-Uptake
- redifferentiation therapy with 13-cis-RA
- available FFPE tissue.
- Eligible criteria for radioiodine-sensitive patients included:
- PTC
- cured after a maximum of two RIT
- no redifferentiation therapy necessary
- available FFPE tissue.
- Exclusion criteria
- DTC other than PTC
- patients lost to follow-up
- other redifferentiation therapy than retinoids
- anaplastic or medullary thyroid cancer
- benign thyroid disease, no available FFPE tissue
- more than two RITs in the control group
- insufficient clinical information.
Exclusion
Key Trial Info
Start Date :
January 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2014
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT03363347
Start Date
January 1 2008
End Date
December 31 2014
Last Update
December 6 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.